

12th Monthly Progress Meeting Minutes (03/12/2024)

WP2:

- **NOVA** has encountered some difficulties with the truncation of the GFAP aptamer and the truncated version is expected by the 13th of December 2024.
- **NOVA** is expected to finalise the selection process for the NfL aptamer(s) by the 13th of December 2024.
- For p-tau 217, **NOVA** is waiting the samples requested from the contact in Cyprus.
 - **NOVA** to follow-up on University of Wurzburg for p-tau and A β proteins.
- **GRAPHEAL** met with the supplier in Shanghai and confirmed that they can provide p-tau217 peptides and antibodies.
 - **GRAPHEAL** informed that the p-tau217 biomarker will be challenging to detect, as the concentration in blood is at the sub-fM level. **Critical decision if there is a need to change the target biomarker.**
 - **UEF** will organise a meeting with their lab team to clarify the current process for p-tau biomarkers. GRAPHEAL, ICN2 and Q-PLAN to be invited. The meeting should take place before the 20th of December 2024.
- **CeADAR** develops an AI/ML model for binding site identification for thrombin.
 - First results are expected by the end of December. Next step is to use the model for GFAP, starting next year.
- AUTH will finalise the experiments with the MNP conjugation with Thrombin by the 13th of December.
 - AUTH will then evaluate MNP conjugation with the truncated GFAP aptamer, results are expected by the 31st of January 2024.

WP3:

- **UP-CATRIN** has procured the NfL and GFAP proteins, and the NfL antibody and arranged to be sent to GRAPHEAL. Some have already delivered, pending items expected in the following weeks.
- **GRAPHEAL** will start working on GFAP towards the GFET sensor development. Results on GFAP are expected by the end of December 2024. Preliminary results on NfL with GFET biosensor are expected by the end of January 2025.
- **UP-CATRIN** can provide structural data of graphene (XPS) to **CeADAR**. A template will be created to start collecting the information.
- **BOTH ICN2 & GRAPHEAL to provide a clear answer regarding the Biosafety Level 2 (BSL2) clearance and alternatives until the end of December:**
 - For the retrospective study, ICN2 and GRAPHEAL need to handle blood fluids/samples from Healthy, SCI /MCI, and/or Alzheimer's Disease subjects.
 - ICN2 has proposed working in another centre (confirmation required).
 - GRAPHEAL is required to have BSL3 due to French regulation, thus a specific space may be required. GRAPHEAL to clarify.

WP4 :

- **GRAPHEAL** will set up a meeting with **ICN2** to discuss blood/plasma separation techniques for the PoC processing of blood samples, by the end of December.
- **GRAPHEAL** will organise a meeting for all WP4 updates by the end of January.
- GRAPHEAL to clarify contribution of other partners in WP4 tasks by the end of January 2025.
- ICN2 and GRAPHEAL to present a timeline for device and app development in the 4th Project Meeting.

WP5 (T5.1):

- **ZI** has confirmed the status of the Ethical Committee approval with UEF. ZI submitted two different protocols for approval. One for the retrospective and one for the prospective. The retrospective did not encounter issues, but the prospective is being “questioned” by their Ethical Committee.
 - UEF informed the consortium of the possibility to change the protocol for all clinical sites to support.
 - Focus also, if required to split the protocol to separate protocols for the retrospective and prospective studies. No need to prepare a regulatory compliant protocol yet.
- **UEF to book a meeting in December, to discuss in more detail next steps and the timeline for the clinical protocol.**
- **UEF** to informally seek advice from FIMEA about the regulatory aspects of the clinical protocol in Finland.

WP6:

- T6.1: Partners are requested to **update the events tab in the action list [here](#)**.
- T6.2: Q-PLAN will run the interviews about results’ exploitation and market analysis in December and January with UP-CATRIN & ICN2. The rest of the partners will follow.
 - AUTH and GRAPHEAL to provide a slot for early January, by the 6th of December
 - Q-PLAN to reach out to NOVA, EVNIA and CeADAR.
- T6.5: GIANCE synergy: 2D-BioPAD discussed the possibility to apply the LCA analysis of GIANCE in the 2D-BioPAD biosensors, and add the 2D-BioPAD to the graphene use cases of GIANCE. Currently GIANCE has 11 use cases, without any biomedical application of graphene. GIANCE is open to sign an NDA. Q-PLAN will send spreadsheet and slides to GRAPHEAL & ICN2. GRAPHEAL & ICN2 to provide their reply by the 13th of December.

WP7:

- T7.4: **Missing financial report to be sent to UP-CATRIN asap.**
- The **review meeting** will take place in **June 2025, together with all GF projects**. One day will be dedicated to 2D-BioPAD’s review. WP leaders will be requested to provide available dates for the review.
 - More information to be shared within January 2025.
- Indicative deadlines (will be updated when new info is available):
 - 19th of May to send presentations of WPs and send the 1st period report to the PO by email
 - 2nd of June to receive questions from the PO and external reviewers
 - 24th of June from 9:00 to 11:00 to have joint review meeting with all GF projects

- **For next period reporting (technical & financial), the template will be distributed at the start of April. All partners will be requested to fill in the template by the end of April. No delays will be accepted, as they may compromise the review process.**
- T7.4: Next project meeting, first option is in Olomouc. ICN2 will provide the dates for SUSNANO meeting. UP-CATRIN & Q-PLAN will discuss slots, possibly near the SUSNANO meeting. Q-PLAN will prepare doodle for all partners to agree on dates for 4th PM.
- If 4th PM not possible in Olomouc, we will examine for Grenoble. Partners required to react quickly, to book slot by the end of December.